CCM
TEVA icon

Copeland Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Copeland Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-12,584
Closed -$456K – 140
2016
Q4 		$456K Sell
12,584
-7,474
-37% -$298K 0.03% 128
2016
Q3 		$923K Sell
20,058
-42,326
-68% -$2.21M 0.06% 125
2016
Q2 		$3.13M Buy
62,384
+2,490
+4% +$133K 0.22% 102
2016
Q1 		$3.21M Buy
59,894
+19,450
+48% +$1.14M 0.22% 102
2015
Q4 		$2.65M Sell
40,444
-334,734
-89% -$20.7M 0.15% 113
2015
Q3 		$21.2M Buy
375,178
+104,955
+39% +$6.81M 1.3% 27
2015
Q2 		$16M Buy
270,223
+12,534
+5% +$773K 0.82% 53
2015
Q1 		$16.1M Sell
257,689
-1,588
-0.6% -$92.3K 1.07% 38
2014
Q4 		$14.9M Buy
259,277
+232,547
+870% +$13M 1.08% 45
2014
Q3 		$1.44M Buy
26,730
+2,601
+11% +$138K 0.15% 63
2014
Q2 		$1.26M Buy
24,129
+7,259
+43% +$371K 0.14% 66
2014
Q1 		$891K Buy
16,870
+4,537
+37% +$210K 0.11% 78
2013
Q4 		$494K Buy
+12,333
New +$486K 0.06% 90

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Copeland Capital Management's TEVA Position: Q1 2017 in Review

Copeland Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2017, closing a stake of 12,584 shares — an estimated $456K sold.

Copeland Capital Management first reported a position in TEVA in Q4 2013 and held it in 13 quarters. The position peaked at $21.2M in Q3 2015. 687 funds tracked by Wall St. Rank hold TEVA as of Q1 2017.

  • Copeland Capital Management reported no remaining Teva Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Copeland Capital Management sold 12,584 Teva Pharmaceuticals shares in Q1 2017, an estimated $456K.
  • Copeland Capital Management first reported a position in Teva Pharmaceuticals in Q4 2013 and held it in 13 quarters.
  • Copeland Capital Management's Teva Pharmaceuticals position peaked at $21.2M in Q3 2015.
  • 687 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2017.

Based on Copeland Capital Management's 13F filing for Q1 2017, filed 2 May 2017.